news
NIH launches antithrombotics trials in COVID-19 patients
The adaptive Phase III trials will assess whether various types and doses of blood thinners can prevent COVID-19 patients forming potentially fatal blood clots.
List view / Grid view
Pulmonary embolism (PE)
news
Servier Canada to market edoxaban in Canada
27 June 2016 | By Victoria White, Digital Content Producer
Edoxaban is an oral anticoagulant that specifically inhibits factor Xa, which is an important factor in the coagulation system that leads to blood clotting...
news
NICE guidance recommends anti-blood clotting drug apixaban
9 June 2015 | By NICE
NICE has recommended the anti-blood clotting drug apixaban as an option for treating and preventing venous thromboembolism (VTE) in adults...
news
Swissmedic approves Lixiana for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation
15 April 2015 | By Daiichi Sankyo
Swissmedic has granted approval of Lixiana for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation...
news
U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk
9 January 2015 | By Daiichi Sankyo
U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk in non-valvular atrial fibrillation and for the treatment of venous thromboembolism...
news
Daiichi Sankyo launches new formulation of LIXIANA® 60 mg Tablets (edoxaban) in Japan
8 December 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has launched a new formulation of LIXIANA®60 mg Tablets...
news
Pradaxa® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism
6 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces that Pradaxa® (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism...
news
FDA approves Pradaxa® for treatment and reduction in risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE)
8 April 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the U.S. Food and Drug Administration has approved Pradaxa® (dabigatran etexilate) for the treatment of DVT and PE...
news
Once-daily edoxaban evaluated in two subgroup analyses of East Asian patients from the largest comparative phase 3 trials of a novel oral anticoagulant
24 March 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced late-breaking data from two pre-specified subgroup analyses of East Asian patients with non-valvular atrial fibrillation or venous thromboembolism enrolled in two phase 3 edoxaban studies...
news
Daiichi Sankyo submits SAVAYSA(TM) (edoxaban) tablets New Drug Application to the U.S. FDA
9 January 2014 | By Daiichi Sankyo
Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism...
news
Daiichi Sankyo submits edoxaban Marketing Authorisation Application to the EMA for once-daily use for stroke prevention in atrial fibrillation and for the treatment and prevention of recurrence of venous thromboembolism
8 January 2014 | By Daiichi Sankyo
Daiichi Sankyo is seeking approval for edoxaban for the prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation...
news
New data analyses show consistent efficacy and safety profile of Pradaxa® in broad range of patients with acute deep vein thrombosis or pulmonary embolism
10 December 2013 | By Boehringer Ingelheim
The efficacy and safety profile of Pradaxa® (dabigatran etexilate) was maintained regardless of patient characteristics...
news
FDA accepts Eliquis® (apixaban) sNDA for review for prophylaxis of deep vein thrombosis following hip or knee replacement surgery
11 July 2013 | By Bristol-Myers Squibb Company
FDA accepted for review a sNDA for Eliquis®
news
Application submitted to the EMA for use of Pradaxa® in treatment of DVT and PE and prevention of recurrent DVT and PE
24 June 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced the submission of an application to the EMA...
news
Perosphere and Daiichi Sankyo enter into a clinical trial agreement
26 April 2013 | By Daiichi Sankyo
Daiichi Sankyo to support and co-sponsor phase 1 Clinical Study...
